Skip to main content

Iqirvo Disease Interactions

There is 1 disease interaction with Iqirvo (elafibranor).

Moderate

Elafibranor (applies to Iqirvo) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The safety and efficacy of elafibranor have not been established in patients with decompensated cirrhosis. Use of elafibranor is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy). Monitor patients with cirrhosis for evidence of decompensation. Consider discontinuing elafibranor if the patient progresses to moderate or severe liver dysfunction (Child-Pugh B or C). No dose adjustment is recommended in patients with mild to moderate liver dysfunction (Child-Pugh A).

Switch to professional interaction data

Iqirvo drug interactions

There are 244 drug interactions with Iqirvo (elafibranor).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer